Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Cash: 2011-2025

Historic Change in Cash for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $3.8 million.

  • Niagen Bioscience's Change in Cash fell 15.44% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.9 million, marking a year-over-year increase of 466.97%. This contributed to the annual value of $17.3 million for FY2024, which is 151.82% up from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Change in Cash is $3.8 million, which was down 21.45% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Change in Cash registered a high of $28.0 million during Q1 2021, and its lowest value of -$7.2 million during Q1 2022.
  • Moreover, its 3-year median value for Change in Cash was $3.3 million (2023), whereas its average is $4.0 million.
  • Its Change in Cash has fluctuated over the past 5 years, first plummeted by 500.57% in 2021, then spiked by 4,465.00% in 2025.
  • Niagen Bioscience's Change in Cash (Quarterly) stood at -$4.9 million in 2021, then spiked by 247.02% to $7.2 million in 2022, then plummeted by 92.31% to $552,000 in 2023, then soared by 2,121.38% to $12.3 million in 2024, then dropped by 15.44% to $3.8 million in 2025.
  • Its last three reported values are $3.8 million in Q3 2025, $4.9 million for Q2 2025, and $11.0 million during Q1 2025.